EUVIMEDEUVIMED entdecken
Qualitative StudieOpen Access

A qualitative study investigating clinician experiences with lecanemab implementation across seven academic medical centers

Ayush Thacker iD, Anna L Parks, Daniel Dohan, Liliana A Ramirez Gomez, Christine S Ritchie, Sachin J Shah, Seth A Gale, Joanna Paladino iD

Journal of Alzheimer’s Disease · 2026-04 · 110 (3) · 1265-1281

DOI: 10.1177/13872877261422486 ↗

Kurz gefasst

Qualitative Studie in der Zeitschrift Journal of Alzheimer’s Disease, online erschienen am 09.03.2026. Verfasst von Ayush Thacker und 7 weiteren Autor:innen. Beteiligte Einrichtung: Massachusetts General Hospital, Mongan Institute Center for Optimal Aging and Serious Illness Research, 125 Nashua Street, Boston, MA, USA. Hauptthemen laut MEDLINE: Alzheimer Disease. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, National Institute on Aging.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The recent approval of anti-amyloid therapies (AATs) for Alzheimer's disease (AD) has introduced new complexities into clinical care. While offering therapeutic promise, AATs necessitate changes in practice models, infrastructure, and team responsibilities. Understanding clinician and system-level adaptations is critical to guide implementation.

Objective

To explore how clinicians adjust clinical workflows and care processes when integrating anti-amyloid treatments into AD management.

Methods

We conducted semi-structured interviews with neurology and geriatrics clinicians across seven academic medical centers to explore perspectives on AAT implementation. An interdisciplinary team used hybrid deductive-inductive coding and thematic analysis to identify themes.

Results

Twenty-seven clinicians (17 neurology, 10 geriatrics) participated. Three themes emerged: (1) Structural adaptations: Sites developed governance committees, eligibility protocols, and workflows for referrals, administration, and monitoring. Some hired new staff, and protocols evolved with experience. (2) Diagnostic shifts: Clinicians reported heightened pressure for earlier, more precise diagnoses, prompting greater biomarker use and structured disclosure visits incorporating treatment discussions. (3) Cultural change: While clinicians described optimism about disease-modifying therapies, they expressed ethical concerns about resource allocation, over-medicalization of early dementia, and diversion of resources from broader dementia care.

Conclusions

The findings reflect evolving institutional protocols, clinical roles and responsibilities, and ethical tensions within the clinical workforce in response to AAT administration and access to early diagnosis and treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseHumansAcademic Medical CentersQualitative ResearchGeriatrics

Stichwörter der Autor:innen

Alzheimer's diseaseanti-amyloid monoclonal antibodiesclinical workflowqualitative methods

Autor:innen und Institutionen

  • Massachusetts General Hospital, Mongan Institute Center for Optimal Aging and Serious Illness Research, 125 Nashua Street, Boston, MA, USA.
  • Division of Hematology and Hematologic Malignancies, University of Utah, Salt Lake City, UT, USA.
  • Institute for Health Policy Studies, University of California San Francisco, San Francisco, CA, USA.
  • Memory Disorders Division, Department of Neurology, Massachusetts General Hospital, Boston, MA, USA.
  • Division of Palliative Care and Geriatric Medicine, Massachusetts General Hospital, Boston, MA, USA.
  • Division of General Internal Medicine, Massachusetts General Hospital, Boston, MA, USA.

ORCID-Profile: Ayush Thacker, Joanna Paladino

Förderung

  • NIA NIH HHS
  • National Institute on Aging

Zitieren

APA

Thacker, A., Parks, A. L., Dohan, D., Ramirez Gomez, L. A., Ritchie, C. S., Shah, S. J., Gale, S. A., & Paladino, J. (2026). A qualitative study investigating clinician experiences with lecanemab implementation across seven academic medical centers. Journal of Alzheimer’s Disease, 110(3), 1265-1281. https://doi.org/10.1177/13872877261422486

Vancouver

Thacker A, Parks AL, Dohan D, Ramirez Gomez LA, Ritchie CS, Shah SJ, et al. A qualitative study investigating clinician experiences with lecanemab implementation across seven academic medical centers. Journal of Alzheimer’s Disease. 2026;110(3):1265-1281. doi:10.1177/13872877261422486

BibTeX
@article{Thacker2026,
  author = {Thacker, Ayush and Parks, Anna L and Dohan, Daniel and Ramirez Gomez, Liliana A and Ritchie, Christine S and Shah, Sachin J and Gale, Seth A and Paladino, Joanna},
  title = {A qualitative study investigating clinician experiences with lecanemab implementation across seven academic medical centers},
  journal = {Journal of Alzheimer’s Disease},
  year = {2026},
  volume = {110},
  number = {3},
  pages = {1265--1281},
  doi = {10.1177/13872877261422486}
}
Kostenlos starten →